Skip to main content
PLOS One logoLink to PLOS One
. 2025 May 23;20(5):e0324620. doi: 10.1371/journal.pone.0324620

Adoption of evidence-based medicine: A comparative study of hospital and community pharmacists in Saudi Arabia

Fahad Alzahrani 1,*, Nawaf Almutairi 2, Abdullah Aloufi 1, Abdulmalik Kattan 3, Abdulaziz Hakeem 3, Mohammed Alharbi 3, Naif Alarawi 3, Haifa A Fadil 1, Ehsan Habeeb 1
Editor: Priti Chaudhary4
PMCID: PMC12101653  PMID: 40408366

Abstract

Objectives

Evidence-based medicine (EBM) combines clinical expertise, patient values, and the best available evidence to guide healthcare decision-making. Despite its importance in pharmacy practice, EBM adoption in Saudi Arabian pharmacies remains under-researched. This study aimed to assess the knowledge, attitudes, and practices regarding EBM among hospital and community pharmacists in the Madinah Region, Saudi Arabia.

Methods

A cross-sectional study was conducted with 206 pharmacists from September to November 2023. Data were collected through a validated online self-administered questionnaire to evaluate pharmacists’ knowledge, attitude, and practice (KAP), as well as their understanding of EBM technical terms.

Ethical approval

The study was approved by the Scientific Ethics Committee of the College of Pharmacy at Taibah University, Madinah region, Saudi Arabia (reference number COPTU-REC-77–20230827). All participants received a consent form before participating.

Results

Pharmacists demonstrated moderate knowledge (76.5%), neutral attitudes (76%), and fair practices (68%) toward EBM, with hospital pharmacists scoring higher than community pharmacists. Moreover, 83.3% believed that EBM could enhance patient health outcomes, 80.0% were willing to learn, and 35.9% believed that EBM focuses solely on research without considering clinical experience. Time constraints (34.0%) were a major barrier, and 46.1% of the participants lacked appropriate training. EBM education was correlated with higher knowledge and attitude scores; however, it had no significant impact on practice scores. Significant barriers identified were the difficulty in conveying technical terms (16%) and limited access to adequate training opportunities.

Conclusion

Despite positive attitudes toward EBM, many pharmacists perceive it as a potential threat to good clinical practice. This perception underscores the need for targeted educational initiatives that promote EBM benefits, address misconceptions, and provide practical support for its integration in both hospital and community pharmacy settings.

Introduction

Over the past decade, evidence-based medicine (EBM) has gained significant attention from healthcare professionals [1]. EBM integrates scientific evidence, clinical expertise, and patient values to improve medical decision-making [2,3].

Traditionally, pharmacy practice has focused on the dispensing of medications, both prescription and over the counter, with pharmacists providing drug-focused services. However, pharmaceutical care shifts this focus toward a more collaborative pharmacist-patient relationship, actively involving the pharmacist in the treatment process [4,5].

EBM in pharmacy practice is essential to deliver pharmaceutical care, as demonstrated by multiple studies showing its significant impact on clinical decision-making accuracy and improved patient outcomes [6,7]. Research has shown that implementing EBM can lead to more rational drug use, enhance patient safety, and reduce medication errors [8,9].

However, adopting an EBM is not without challenges. Pharmacists and other healthcare professionals often encounter barriers such as time constraints, limited access to resources, difficulties in understanding statistical terminology, and gaps in the knowledge and skills needed to search for and appraise evidence [10,11]. Moreover, the application of EBM must be balanced with individual patient circumstances and preferences.[12].

Saudi Arabia has examined the perceptions, attitudes, and use of EBM among healthcare professionals, including pharmacists. These studies consistently revealed a positive attitude toward EBM, with professionals recognizing its potential to enhance patient care. Nonetheless, significant organizational, professional, and interprofessional barriers continue to hinder the widespread implementation [11,13,14].

Hospital pharmacists typically work in structured environments that foster professional development and facilitate the integration of EBM into their practice. They often collaborate within multidisciplinary teams, which enhances opportunities for knowledge sharing and the practical application of EBM principles [15]. In contrast, community pharmacists face distinct challenges, such as high workloads and limited access to continuing education programs, which can hinder their ability to incorporate EBM into daily practice [16,17]. Chun and Anwer added that, unlike their hospital counterparts, community pharmacists often work independently, necessitating tailored strategies and targeted support to adopt EBM in their professional routines effectively [18].

While previous research has examined EBM adoption among hospital pharmacists in Saudi Arabia [13,19], there is a significant lack of studies investigating EBM implementation in community pharmacy settings. This significant research gap is particularly concerning given that community pharmacists serve as primary healthcare providers for many patients [20]. Furthermore, no studies have directly compared EBM knowledge, attitudes, and practices between hospital and community pharmacists, limiting our understanding of how different practice settings influence evidence-based practice implementation. To bridge this gap, this study aimed to address the existing research gap by comprehensively assessing the knowledge, attitudes, and practices regarding EBM among hospital and community pharmacists in the Madinah region of Saudi Arabia.

Methods

Study design and settings

A cross-sectional study was conducted among community and hospital pharmacists in the Madinah region of Saudi Arabia from September to November 2023 to collect data on the knowledge, attitudes, and practices of EBM using a self-reported online questionnaire created with Google Forms.

The study included licensed community and hospital pharmacists with a bachelor’s degree or higher who were working full-time in the Madinah region of Saudi Arabia. Pharmacists employed in other sectors, such as pharmaceutical companies, manufacturing, or academia, were excluded as they are typically not involved in direct patient care or clinical decision-making where evidence-based medicine is applied. Moreover, those practicing outside the specified region, pharmacy technicians, individuals who declined to participate, or respondents who did not complete the full survey were also excluded from the study.

Study sampling and response rate

Hospital pharmacists were recruited using convenience sampling from various government and private hospitals across the Madinah region. Eight trained research assistants obtained recruitment and consent in person, having received comprehensive training on standardized data collection protocols and ethical research practices before study commencement.

For community pharmacists, convenience sampling was the primary recruitment strategy, supplemented by snowball sampling. The study was promoted through internal distribution lists at several local independent and chain pharmacies, and participants were encouraged to share the invitation with eligible colleagues. This approach was necessary due to the absence of a comprehensive and accessible sampling frame for pharmacists in the Madinah region.

A total of 540 pharmacists were invited to participate in the study, of whom 276 completed the questionnaire in whole or in part, yielding an initial response rate of 51.11%. After excluding incomplete and ineligible responses, 206 valid questionnaires were retained for analysis, resulting in a final valid response rate of 38.15%.

Data collection

An online validated questionnaire was used for data collection, which the researchers developed based on the Noor EBM questionnaire [21]. The questions on EBM barriers and practices were adapted with input from experts and relevant literature [2224]. The questionnaire was reviewed by three academics and two community pharmacists and piloted for clarity. Pharmacy graduates (n = 32) completed the survey twice within 30 minutes to 1 hour, with score stability tested using the test-retest method. Pearson’s correlation showed significant score stability (r > 0.94, p < 0.01), exceeding the acceptable threshold of 80% [25]. Internal consistency was confirmed with a Cronbach’s alpha of 91.2% and domain-specific alphas of 90.0%, 93.0%, and 91.0% for EBM knowledge, attitude, and practice, respectively.

The survey contained 40 questions across four areas: (1) professional traits, (2) self-assessed EBM knowledge, (3) attitudes and actions toward EBM, and (4) experiences with EBM, mainly statistical terms. Responses were collected using a 5-point Likert scale and grouped into Agree, Neutral, and Disagree categories. Net agreement scores were calculated by subtracting disagreement from agreement percentages, ranging from -100% to +100%, where positive scores indicated agreement. Similarly, a net frequency score was computed by subtracting low-frequency (“Never” and “Rarely”) from high-frequency (“Frequently” and “Very Frequently”) responses, with positive values reflecting higher reported behavior frequency. Comparable net scoring methods have been employed in survey research to efficiently summarize ordinal responses and enable meaningful comparisons across groups or time periods [26,27].

The total scores for each section—knowledge, attitude, and practice—were converted into percentage scores by dividing the raw scores by the maximum possible score and multiplying by 100. Classification was based on Bloom’s cut-off points, a widely used method in KAP studies. Scores of 60–79% were categorized as moderate knowledge, neutral attitudes, and adequate EBM practices, while scores above 79% indicated excellent knowledge, positive attitudes, and proficient practices. Scores below 60% reflected limited knowledge, negative attitudes, and poor practices [28]. This approach provides a standardized and interpretable framework for assessing EBM-related competencies, consistent with previous health research [2931].

Data analysis

Data collected via Google Forms was transferred to an Excel spreadsheet and coded for statistical analysis. IBM SPSS Statistics version 27 was used for the analysis. Descriptive statistics, including means, standard deviations, total scores, frequencies, and percentages, were calculated. Due to non-normal data distribution, non-parametric tests were used. The Mann-Whitney U test and the Kruskal-Wallis test were applied, followed by Dunn’s test for multiple pairwise comparisons. The significance level (α) for all statistical tests was set at 0.05, and two-tailed tests were employed throughout the analysis. Effect size was evaluated using Cohen’s d. Based on Cohen’s guidelines, an effect size of 0.2 indicates a small effect, 0.5 a medium effect, and 0.8 or greater a large effect. A small effect (d ≈ 0.2) reflects a modest difference between groups that, although potentially statistically significant, may have limited practical relevance [32].

Results

Pharmacists’ characteristics

The mean age was comparable between hospital (31.58 ± 5.4 years) and community pharmacists (31.06 ± 5.15 years). Gender distribution showed significant variation, with community pharmacies having predominantly male practitioners (90.0%) compared to hospitals showing more gender diversity (56.6% male, 43.4% female). Educational qualifications differed markedly between settings. Hospital pharmacists demonstrated higher academic achievements, with 44.3% holding PharmD degrees. In contrast, community pharmacists primarily held B-Pharm degrees (81.0%).

The source of education emerged as a distinctive factor; 92.5% of hospital pharmacists graduated from Saudi universities, while 67.0% of community pharmacists received foreign education. Experience distribution revealed that half of hospital pharmacists (50.0%) had 0–5 years of practice, whereas community pharmacists showed a more even distribution across experience levels, with 37.0% having over 10 years of experience. Regarding EBM training, hospital pharmacists reported higher participation rates (59.5%) compared to community pharmacists (47.0%). The comprehensive demographic and professional characteristics of the study pharmacists are detailed in Table 1.

Table 1. Pharmacists’ demographic and professional characteristics.

Characteristics Hospital pharmacists Community pharmacists
n (%) n (%)
Age, years n (SD) 31.58 ± 5.4 31.06 ± 5.15
Gender
Male 60 (56.6) 90 (90.0)
Female 46 (43.4) 10 (10.0)
Level of Education
Bachelor’s Degree in Pharmacy (B-Pharm) 46 (43.4) 81 (81.0)
Bachelor’s Degree in Doctor of Pharmacy (PharmD) 47 (44.3) 16 (16.0)
Postgraduate (MSc, PhD) in Pharmacy 13 (12.3) 3 (3.0)
Source of Education
Saudi University 98 (92.5) 33 (33.0)
Foreign University 7 (7.5) 67 (67.0)
Years of Experience
0–5 53 (50.0) 39 (39.0)
6–10 29 (28.3) 24 (24.0)
 > 10 23 (21.6) 37 (37.0)
Attended an Education/Training Program on EBM
Yes 63 (59.5) 47 (47.0)
No 43 (40.5) 53 (53.0)

Knowledge of EBM

Table 2. highlights pharmacists’ knowledge and perceptions of EBM. Most (84.4%) agreed that EBM involves critically appraising research for clinical decision-making. However, 41.7% of the pharmacists believed EBM focuses solely on research without considering clinical experience, with a low net agreement of 5.8%. Approximately 47.0% prioritized patient preferences over clinician preferences, with a net agreement of 25.2%. A significant majority of pharmacists (81.1%) felt that EBM improved their understanding of research methodology, with a high net agreement of 79.7%. EBM’s applicability in clinical uncertainty was acknowledged by 73.3%, and 59.9% recognized the Cochrane Library as a key resource. Additionally, 65.5% agreed that difficulty in understanding statistical terms hinders EBM application, with a net agreement of 60.2%.

Table 2. Pharmacists’ knowledge of EBM.

Statement SA/A N SD/D Positive responses Negative responses Net agreement
EBM involves the process of critically appraising research findings as the basis for making the best clinical decision 174 32 0 84.4% 0.0% 84.4%
EBM focuses on the best currently available research without considering clinical experience. 86 46 74 41.7% 35.9% 5.8%
Patients’ preferences should be prioritized over clinicians’ preferences in making clinical decisions 97 64 45 47.0% 21.8% 25.2%
EBM improves clinicians’ understanding of research methodology 168 35 (17) 3 81.1% 1.4% 79.7%
EBM can be practiced in situations where there is doubt about any aspect of clinical management 151 47 8 73.3 3.9% 69.4%
The increasing number of systematic reviews that are applicable to practice can be found in the Cochrane Library 122 79 5 59.9% 2.4% 57.5
Difficulty in understanding statistical terms is the major setback in applying evidence-based medicine 135 59 11 65.5% 5.3% 60.2%
Total Score Means (%) General Impression
5444/7210 26.5 (76.5) Moderate Knowledge

SD = Strongly Disagree, D = Disagree, N = Neutral, A = Agree, SA = Strongly Agree.

Net Agreement = (% Agree + % Strongly Agree) - (% Strongly Disagree + % Disagree.

Attitude toward EBM

Most pharmacists (83.3%) agreed that practicing EBM improves patient outcomes, with a high net agreement of 81.4%. Additionally, 80.0% of pharmacists expressed willingness to learn or practice EBM (net agreement of 79.6%). A majority (78.8%) of the pharmacists believed that EBM enhances work effectiveness, and 78.6% felt that it is essential for pharmacists to update their EBM knowledge continually. However, 51.2% of the pharmacists perceived EBM as a potential threat to good clinical practice (net agreement 24.3%). There was mixed sentiment on experience versus EBM, with 40.3% favoring experience (net agreement 18%). Moreover, 57.7% believed understanding basic disease mechanisms suffices for good practice (net agreement of 38.3%), and 50.0% felt reading systematic review conclusions is adequate (net agreement of 28.7%). Further details on pharmacists’ attitudes toward EBM are in Table 3.

Table 3. Pharmacists’ attitude toward EBM.

Statement SA/A N SD/D Positive responses Negative responses Net agreement
I believe that EBM is a threat to good clinical practice 107 44 55 51.2% 26.9% 24.3%
Practicing EBM can improve patient health outcomes 171 31 4 83.3% 1.9% 81.4%
I am willing to learn/practice EBM if given the opportunity. 166 39 1 80.0% 0.4% 79.6%
I feel that research findings are very important in my day-to-day management of patients 161 40 5 78.1% 2.4% 75.7%
I believe years of experience are more valuable than EBM 83 77 46 40.3% 22.3% 18%
I am convinced that applying EBM in practice increases the effectiveness of my work 162 38 6 78.8% 2.9% 75.9%
I am confident that understanding the basic mechanisms of disease is sufficient for good clinical practice 119 47 40 57.7% 19.4% 38.3%
I feel that access to databases is vital in obtaining journals on EBM 138 62 7 66.9% 3.4& 63.5%
I feel that reading the conclusions of a systematic review is adequate for clinical practice 103 59 44 50.0% 21.3% 28.7%
I think it is mandatory to continuously update pharmacists’ knowledge/education in EBM to deliver efficient patient care 162 39 5 78.6% 2.4% 76.2%
Total Score Means (%) General Impression
7827/10300 38 (76) Neutral Attitude

SD = Strongly Disagree, D = Disagree, N = Neutral, A = Agree, SA = Strongly Agree;

Net Agreement = (% Agree + % Strongly Agree) - (% Strongly Disagree + % Disagree).

Practice of EBM

The data show that 51.4% of pharmacists frequently or very frequently apply EBM, with a net frequency of 37%. A high proportion (85.5%) of pharmacists reported using multiple search engines for systematic reviews, with a net frequency of 72.4%. However, time constraints hinder EBM practice, with 34.0% of pharmacists frequently lacking time to study or apply it (net frequency 15.6%). Continuous medical education on EBM was frequently engaged by 40.7% of pharmacists (net frequency 17.9%), and 43.6% frequently shared EBM knowledge with colleagues (net frequency 26.1%), indicating a positive trend in evidence-based culture. Additionally, 41.7% of the pharmacists frequently used the PICO format to translate clinical questions, with a net frequency of 20.9%, suggesting moderate adoption of this EBM skill. Further statistics on pharmacists’ EBM practices are in Table 4.

Table 4. Pharmacists’ practice of EBM.

Statement F/VF O R/N High Frequency Low Frequency Net Frequency
I apply EBM in practice 106 71 29 51.4% 14.0% 37%
I use multiple search engines for systematic reviews 95 81 27 85.5% 13.1% 72.4%
I do not have enough time to study/practice EBM 70 98 38 34.0% 18.4% 15.6%
I join Continuous Medical Education for an update regarding EBM 84 75 47 40.7% 22.8% 17.9%
I promote and share knowledge about EBM with my colleagues at the workplace 90 80 36 43.6% 17.5% 26.1%
I usually translate a clinical question into a form that can be answered from the literature (PICO)a 86 77 43 41.7% 20.8% 20.9%
Total Score Means (%) General Impression
4211/6180 21.2 (68) Fair Practice

aPICO; P = Patient or Population; I = Intervention or Indicator; C = Comparison or Control; O = Outcome; T = Time or Type. N = Never, R = Rarely, O = Occasionally, F = Frequently, VF = Very Frequently. High. Net Frequency = (% Frequently + % Very Frequently) - (% Never + % Rarely).

Statistical terms in EMB

The survey analysis revealed that pharmacists had varied levels of understanding of statistical terms. Accordingly, 52.4% found clinical effectiveness to be the most understandable, whereas heterogeneity was found to be challenging, with 24% lacking any understanding. Additionally, 5% of pharmacists felt that understanding confidence intervals (CI) would not benefit them, while 18.4% showed interest in learning more about CIs despite limited understanding. 18.4% reported not understanding the odds ratio, 17.0% did not comprehend absolute risk, and 15.0% lacked an understanding of relative risk. Furthermore, only 33% of pharmacists were able to understand and explain “the number needed to treat.” Fig 1 summarizes pharmacists’ responses, highlighting their comprehension and interest in further learning of EBM-related technical terms.

Fig 1. Pharmacists’ awareness of technical terms used in EMB.

Fig 1

Association between pharmacists’ demographics and KAP scores

Table 5 explores the association between pharmacists’ demographic characteristics and their KAP scores related to EBM. The analysis of KAP scores between hospital and community pharmacists revealed significant differences in knowledge and practice domains. Hospital pharmacists exhibited significantly higher knowledge scores (M = 3.84, SD = 0.52) than community pharmacists (M = 3.70, SD = 0.57), with a p-value of 0.03 and an effect size of 0.20. No significant difference was found between the two groups in attitude scores. In the practice domain, hospital pharmacists again outperformed community pharmacists (M = 3.89, SD = 0.51 vs. M = 3.76, SD = 0.58), with a p-value of 0.03 and an effect size of 0.22. Both effect sizes indicate a small effect according to Cohen’s classification.

Table 5. Association between pharmacists’ demographic characteristics and knowledge, attitude, and practice.

Demographic Characteristics Knowledge score Attitude Score Practice score
Mean ± SD p-value Mean ± SD p-value Mean ± SD p-value
Age 0.35 0.22 0.72
20-30 3.75  ± 0.52 3.83  ± 0.49 3.85  ± 0.48
31-40 3.77  ± 0.57 3.76  ± 0.53 3.79  ± 0.52
41-50 4.01  ± 0.62 3.81  ± 0.71 4.02  ± 0.74
51-60 -
Gender 0.82 0.34 0.98
Male 3.77  ± 0.56 3.83  ± 0.52 3.83  ± 0.53
Female 3.78  ± 0.52 3.74  ± 0.49 3.83  ± 0.54
Practice Settings 0.03* 0.60 0.02*
Hospital Pharmacists 3.84  ± 0.52 3.83  ± 0.50 3.89  ± 0.51
Community Pharmacists 3.70  ± 0.57 3.76  ± 0.53 3.76  ± 0.58
Level of Education 0.35 0.84 0.87
Bachelor’s Degree in Pharmacy (B-Pharm) 3.81  ± 0.58 3.83  ± 0.545 3.81  ± 0.54
Bachelor’s Degree in Doctor of Pharmacy (PharmD) 3.80  ± 0.59 3.79  ± 0.54 3.86  ± 0.53
Postgraduate (MSc/PhD) in Pharmacy 3.90  ± 0.46 3.72  ± 0.57 3.84  ± 0.55
Source of Education 0.54 0.63 0.09
Saudi University 3.78  ± 0.54 3.81  ± 0.53 3.86  ± 0.53
Foreign University 3.75  ± 0.57 3.76  ± 0.50 3.76  ± 0.54
Years of Experience 0.05 0.74 0.01*
< 1 3.88  ±  0.53 3.97  ± 0.51 4.12  ± 0.45
1–5 3.69  ± 0.50 3.71  ± 0.47 3.78  ± 0.57
6–10 3.65  ± 0.47 3.78  ± 0.44 3.68 ± 0.42
 > 10 3.78  ± 0.63 3.86  ± 0.60 3.90  ± 0.58
Attended an Education/Training Program on EBM 0.04* 0.03* 0.75
Yes 3.85  ± 0.50 3.89  ± 0.47 3.83  ± 0.48
No 3.68  ± 0.55 3.69  ± 0.54 3.83  ± 0.58

*Significant p-value

The study also found that years of experience were significantly associated with practice scores (p = 0.01), with pharmacists having less than one year of experience reporting higher practice scores than those with 1–5 or 6–10 years of experience. Additionally, attending EBM training programs was associated with slightly higher knowledge (p = 0.04, effect size = 0.19) and practice scores (p = 0.03, effect size = 0.20). Both effect sizes indicate a small effect according to Cohen’s classification.

Discussion

This study provides valuable insights into the KAP of EBM among hospital and community pharmacists in the Madinah region of Saudi Arabia. Our research extends previous work by providing the first direct comparison of EBM implementation between practice settings, revealing significant differences in adoption patterns. Building upon earlier hospital-focused studies [13], the study findings demonstrate the impact of practice environment on EBM implementation, with hospital pharmacists showing higher knowledge scores compared to community pharmacists. The findings reveal a generally positive attitude toward EBM but highlight areas for improvement and potential barriers to its implementation. The results indicate a moderate to high level of knowledge about EBM principles among pharmacists. The majority of pharmacists (84.4%) correctly identified EBM as involving the critical appraisal of research for clinical decision-making, aligning with Tebala’s seminal definition of EBM [33]. However, there was some confusion regarding the role of clinical experience in EBM, with 41.7% of the participants believing that EBM focuses solely on research evidence. This misconception suggests a need for clarification on the integration of research evidence with clinical expertise and patient values, as Wieten emphasized in their discussion of EBM principles [34]. The high agreement (81.1%) that EBM improves the understanding of research questions and methodology is encouraging, as it suggests that pharmacists recognize the value of EBM when enhancing their professional skills. This finding is consistent with those of Landey and Sibbld, who reported similar perceptions among healthcare professionals [35].

The study revealed generally positive attitudes toward EBM, with 83.3% agreeing that EBM can improve patient health outcomes. This is consistent with the findings of Abu Farha et al., who reported positive attitudes toward EBM among Jordanian pharmacists [9]. The high willingness to learn and practice EBM (80.0%) indicates a receptive environment for further EBM education and implementation initiatives. However, the perception of EBM as a potential threat to good clinical practice by 51.2% of respondents is concerning. This could stem from misunderstandings about EBM’s role in clinical decision-making or concerns about the devaluation of clinical experience. Similar concerns have been noted in other studies, such as those by Haynes et al., highlighting the need for education that emphasizes EBM as a complement to, rather than a replacement for, clinical expertise [36].

The EBM practice among pharmacists showed room for improvement. Although 51.4% frequently reported applying EBM in practice, only 41.7% regularly used the PICO format to translate clinical questions. This gap between knowledge and practice is common and has been observed in other healthcare settings [37].

The high frequency of systematic reviews on multiple search engines (85.5%) is encouraging, suggesting that pharmacists actively seek evidence. However, the reported time constraints (34.0% frequently lacking time for EBM) repeat findings from other studies and highlight a significant barrier to EBM implementation [13].

The study identified significant differences between hospital and community pharmacists regarding their EBM-related knowledge and practice. Hospital pharmacists demonstrated marginally higher scores, which may be attributed to the structured hospital environment that fosters continuous professional development and collaboration with other healthcare professionals [38]. However, the lower EBM scores among community pharmacists cannot be explained solely by differences in practice settings.

Several additional factors likely contribute to this disparity. Community pharmacists often face limited access to evidence-based resources, lack formal clinical support systems, and experience greater time constraints due to higher workload demands [39,40]. Unlike hospital pharmacists, who typically work within multidisciplinary teams and benefit from access to institutional guidelines and electronic databases, community pharmacists may lack the infrastructure necessary to support regular engagement with EBM practices [41].

To bridge this gap, targeted interventions are needed. Improving access to clinical resources, reducing workload burdens, and providing structured EBM training tailored to community pharmacy settings could significantly enhance the uptake of EBM [42,43]. Strengthening these areas may help support the broader and more consistent application of EBM practices across both hospital and community pharmacy sectors.

The influence of experience on EBM adoption reveals an interesting paradox: pharmacists with less than one year of experience scored higher in knowledge, attitudes, and practice (KAP) compared to their more experienced counterparts. One possible explanation is that recent graduates may have received more formal and updated training in evidence-based medicine (EBM) due to changes in pharmacy curricula. In contrast, pharmacists with more years of experience may not have had the same level of EBM emphasis during their initial training, which may explain the lower practice scores among this group [4446]. Another contributing factor could be that younger pharmacists generally show greater interest in applying EBM compared to older pharmacists, as previous research suggests that both age and years of experience can influence EBM implementation in practice [47]. This trend is consistent with findings in other health professions, where integrated EBM curricula have been shown to significantly improve information literacy and evidence application skills among students and recent graduates [48].

The positive impact of EBM training on knowledge and attitude scores, but not on practice scores, suggests a gap between theoretical understanding and practical application. Studies have indicated that although healthcare professionals often demonstrate improved knowledge and positive attitudes following EBM training, the translation of this knowledge into practice remains insufficient due to barriers such as time constraints, lack of access to resources, and insufficient integration of EBM into daily routines [19,49].

The study also identified a significant barrier: 41.7% of pharmacists mistakenly believed that EBM disregards clinical experience. This misconception reflects a fundamental misunderstanding of EBM’s core principle, which emphasizes the integration of clinical expertise, the best available research evidence, and patient values. Therefore, addressing this misunderstanding is essential to promote a more accurate and balanced perception of EBM among pharmacists and to support its broader adoption in practice.

Recommendations for enhancing EBM adoption among pharmacists

Overcoming the barriers to EBM adoption identified in this study requires a comprehensive, multi-faceted approach that addresses both individual competencies and systemic support structures. One recommended approach is the implementation of blended learning models that combine face-to-face workshops with online modules, focusing on key competencies such as evidence appraisal, database searching, and the application of research findings to clinical scenarios [50]. Furthermore, short, targeted workshops and flexible, self-paced online courses could better accommodate the busy schedules of practicing pharmacists. Mentorship programs, in particular, offer an additional layer of continuous, real-world support, helping pharmacists to translate EBM principles into their daily routines [51,52]. Beyond individual training, institutional support plays a vital role in facilitating EBM adoption. Organizations can embed clinical decision-support tools into pharmacists’ workflows, provide protected time specifically for EBM-related activities, and encourage interdisciplinary collaboration. By implementing these multi-faceted strategies, institutions can help build both the confidence and competency required for pharmacists to consistently apply EBM in everyday practice [5255].

Limitations of the study

Several limitations should be considered when interpreting the results of this study. First, the study design, which utilized Google Forms’ branching logic to exclude diploma-holding pharmacy technicians, non-participants, and incomplete responses, prevented the collection of comparative data, thereby limiting the ability to assess selection bias. Second, the achieved response rate of 38.15% and the relatively young average age of participants may impact the representativeness of the findings. Third, the focus on pharmacists within the Madinah region, coupled with the use of a convenience sampling method, restricts the generalizability of the results to other regions of Saudi Arabia. Additionally, the self-administered nature of the questionnaire may have introduced social desirability bias, potentially leading to an overestimation of EBM knowledge and practices. Finally, the cross-sectional study design precludes the assessment of temporal changes in EBM adoption patterns over time.

Conclusion

This study reveals significant variations in Evidence-Based Medicine (EBM) implementation between hospital and community pharmacists in the Madinah region, with hospital pharmacists demonstrating slightly higher knowledge and practice scores. Despite generally positive attitudes toward EBM, with 83.3% believing it improves patient outcomes, significant barriers persist, including time constraints and insufficient training. The findings suggest that EBM education positively influences knowledge and practice, though its impact on attitudes remains limited. These results highlight the need for targeted interventions, particularly for community pharmacists, focusing on practical EBM application and addressing workplace-specific barriers. Future initiatives should emphasize continuous professional development, workplace support systems, and integrated EBM training programs that bridge the gap between theoretical knowledge and practical application.

AcknowledgmentsThe authors of this study acknowledge the contribution of the pharmacists who participated in this study.

Data Availability

All relevant data are within the article and its Supporting Information files. The datasets necessary to replicate the study findings and the supporting files have also been deposited in the Zenodo public data repository. The data can be accessed at the following DOI: 10.5281/zenodo.15332654.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Lehane E, Leahy-Warren P, O’Riordan C, Savage E, Drennan J, O’Tuathaigh C. Evidence-based practice education for healthcare professions: an expert view. BMJ Evid Based Med. 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Sackett D, Rosenberg W, Gray J, Haynes R, Richardson W. Evidence based medicine: what it is and what it isn’t. BMJ. 1996:71–2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Sackett DL, editor. Evidence-based medicine. Seminars in perinatology. 1997: Elsevier. [DOI] [PubMed] [Google Scholar]
  • 4.Wiedenmayer K, Summers RS, Mackie CA, Gous AG, Everard M, Tromp D. Developing Pharmacy Practice: A Focus On Patient Care: Handbook. World Health Organization. 2006. [Google Scholar]
  • 5.Toklu HZ, Hussain A. The changing face of pharmacy practice and the need for a new model of pharmacy education. J Young Pharm. 2013;5(2):38–40. doi: 10.1016/j.jyp.2012.09.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dieu D. Evidence-based medicine and evidence-based pharmacy in medical practice. Int J Sci Eng Res. 10:1253–5. [Google Scholar]
  • 7.Connor L, Dean J, McNett M, Tydings DM, Shrout A, Gorsuch PF, et al. Evidence-based practice improves patient outcomes and healthcare system return on investment: findings from a scoping review. Worldviews Evid Based Nurs. 2023;20(1):6–15. doi: 10.1111/wvn.12621 [DOI] [PubMed] [Google Scholar]
  • 8.Sun J, Chen G-M, Huang J. Effect of evidence-based pharmacy care on satisfaction and cognition in patients with non-valvular atrial fibrillation taking rivaroxaban. Patient Prefer Adherence. 2021;15:1661–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Abu Farha R, Alefishat E, Suyagh M, Elayeh E, Mayyas A. Evidence-based medicine use in pharmacy practice: a cross-sectional survey. J Eval Clin Pract. 2014;20(6):786–92. doi: 10.1111/jep.12212 [DOI] [PubMed] [Google Scholar]
  • 10.Majid S, Foo S, Luyt B, Zhang X, Theng Y-L, Chang Y-K, et al. Adopting evidence-based practice in clinical decision making: nurses’ perceptions, knowledge, and barriers. J Med Libr Assoc. 2011;99(3):229–36. doi: 10.3163/1536-5050.99.3.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Alshehri AA, Al-Khowailed MS, Alnuaymah FM, Alharbi AS, Alromaihi MS, Alghofaili RS, et al. Knowledge, attitude, and practice toward evidence-based medicine among hospital physicians in Qassim Region, Saudi Arabia. Int J Health Sci (Qassim). 2018;12(2):9–15. [PMC free article] [PubMed] [Google Scholar]
  • 12.Gupta M. Improved health or improved decision making? The ethical goals of EBM. J Eval Clin Pract. 2011;17(5):957–63. doi: 10.1111/j.1365-2753.2011.01743.x [DOI] [PubMed] [Google Scholar]
  • 13.Al-Jazairi AS, Alharbi R. Assessment of evidence-based practice among hospital pharmacists in Saudi Arabia: attitude, awareness, and practice. Int J Clin Pharm. 2017;39(4):712–21. doi: 10.1007/s11096-017-0430-x [DOI] [PubMed] [Google Scholar]
  • 14.Ashri N, Al-Amro H, Hamadah L, Al-Tuwaijri S, El Metwally A. Dental and medical practitioners’ awareness and attitude toward evidence based practice in Riyadh, Saudi Arabia. A comparative study. The Saudi Journal for Dental Research. 2014;5(2):109–16. doi: 10.1016/j.ksujds.2013.11.003 [DOI] [Google Scholar]
  • 15.Lee KMK, Koeper I, Johnson ME, Page A, Rowett D, Johnson J. Multidisciplinary perspectives on roles of hospital pharmacists in tertiary settings: a qualitative study. Int J Qual Health Care. 2024;36(1):mzad110. doi: 10.1093/intqhc/mzad110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Alshaiban A, Alavudeen SS, Alshahrani I, Kardam AM, Alhasan IM, Alasiri SA, et al. Impact of clinical pharmacist running anticoagulation clinic in Saudi Arabia. J Clin Med. 2023;12(12):3887. doi: 10.3390/jcm12123887 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Atkinson J, Sánchez Pozo A, Rekkas D, Volmer D, Hirvonen J, Bozic B, et al. Hospital and community pharmacists’ perceptions of which competences are important for their practice. Pharmacy (Basel). 2016;4(2):21. doi: 10.3390/pharmacy4020021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.De Chun L, Anwar M. What constitutes evidence for over-the-counter medicines? A cross-sectional study of community pharmacists’ knowledge, attitude, and practices. Journal of Pharmaceutical Health Services Research. 2023;14(2):212–20. doi: 10.1093/jphsr/rmad017 [DOI] [Google Scholar]
  • 19.Bahmaid RA, Karim M, Al-Ghamdi N, Al-Tannir M. Impact of research educational intervention on knowledge attitudes perceptions and pharmacy practices towards evidence-based medicine among junior pharmacists. Cureus. 2018;10(6). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ihekoronye MR, Osemene KP. Evaluation of the participation of community pharmacists in primary healthcare services in Nigeria: a mixed-method survey. Int J Health Policy Manag. 2022;11(6):829–39. doi: 10.34172/ijhpm.2020.224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Norhayati MN, Nawi ZM. Validity and reliability of the noor evidence-based medicine questionnaire: a cross-sectional study. PLoS One. 2021;16(4):e0249660. doi: 10.1371/journal.pone.0249660 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Sadeghi-Bazargani H, Tabrizi JS, Azami-Aghdash S. Barriers to evidence-based medicine: a systematic review. J Eval Clin Pract. 2014;20(6):793–802. doi: 10.1111/jep.12222 [DOI] [PubMed] [Google Scholar]
  • 23.McKenna HP, Ashton S, Keeney S. Barriers to evidence-based practice in primary care. J Adv Nurs. 2004;45(2):178–89. doi: 10.1046/j.1365-2648.2003.02879.x [DOI] [PubMed] [Google Scholar]
  • 24.Windle PE. Moving beyond the barriers for evidence-based practice implementation. Journal of Perianesthesia Nursing. 2006;21(3):208–11. [DOI] [PubMed] [Google Scholar]
  • 25.Guttman L. A basis for analyzing test-retest reliability. Psychometrika. 1945;10:255–82. doi: 10.1007/BF02288892 [DOI] [PubMed] [Google Scholar]
  • 26.Reichheld FF. The One Number You Need to Grow. Harvard Business Review. 2003. [PubMed] [Google Scholar]
  • 27.Duda R, Hart P. Pattern classification. John Wiley & Sons. 2006. [Google Scholar]
  • 28.Bloom BS. Learning for Mastery. Instruction and Curriculum. Regional Education Laboratory for the Carolinas and Virginia, Topical Papers and Reprints, Number 1. Evaluation Comment. 1968;1(2):n2. [Google Scholar]
  • 29.Wang L, Abualfoul M, Oduor H, Acharya P, Cui M, Murray A, et al. A cross-sectional study of knowledge, attitude, and practice toward COVID-19 in solid organ transplant recipients at a transplant center in the United States. Front Public Health. 2022;10:880774. doi: 10.3389/fpubh.2022.880774 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Alibrahim D, El Mahalli A. The knowledge, attitude and practice level of dental auxiliaries regarding oral health care for pregnant patients in the eastern province of Saudi Arabia. F1000Res. 2022;11:216. doi: 10.12688/f1000research.72903.3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Deeb N, Naja F, Nasreddine L, Kharroubi S, Darwiche N, Hwalla N. Nutrition knowledge, attitudes, and lifestyle practices that may lead to breast cancer risk reduction among female university students in Lebanon. Nutrients. 2024;16(7):1095. doi: 10.3390/nu16071095 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Cohen J. Statistical power analysis for the behavioral sciences. Routledge. 2013. [Google Scholar]
  • 33.Tebala GD. The emperor’s new clothes: a critical appraisal of evidence-based medicine. Int J Med Sci. 2018;15(12):1397–405. doi: 10.7150/ijms.25869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wieten S. Expertise in evidence-based medicine: a tale of three models. Philosophy Ethics Humanities Med. 2018;13:1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Landry MD, Sibbald WJ. From data to evidence: evaluative methods in evidence-based medicine. Respir Care. 2001;46(11):1226–35. [PubMed] [Google Scholar]
  • 36.Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. BMJ Evidence-Based Medicine. 2002;7(2):36–8. doi: 10.1136/ebm.7.2.36 [DOI] [PubMed] [Google Scholar]
  • 37.Ahmad Ghaus MG, Tuan Kamauzaman TH, Norhayati MN. Knowledge, attitude, and practice of evidence-based medicine among emergency doctors in Kelantan, Malaysia. Int J Environ Res Public Health. 2021;18(21):11297. doi: 10.3390/ijerph182111297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Atkinson J, Sánchez Pozo A, Rekkas D, Volmer D, Hirvonen J, Bozic B, et al. Hospital and community pharmacists’ perceptions of which competences are important for their practice. Pharmacy (Basel). 2016;4(2):21. doi: 10.3390/pharmacy4020021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Alzahrani F, Khairi NB, Alattas BO, Alrehaili TH, Aljehani GS, Alahmadi RB, et al. Community pharmacists’ readiness for minor ailment services in Saudi Arabia: a cross-sectional study of perceptions, barriers, and facilitators. Int J Pharm Pract. 2025;33(2):197–204. doi: 10.1093/ijpp/riae067 [DOI] [PubMed] [Google Scholar]
  • 40.Newman TV, Hernandez I, Keyser D, San-Juan-Rodriguez A, Swart ECS, Shrank WH, et al. Optimizing the role of community pharmacists in managing the health of populations: barriers, facilitators, and policy recommendations. J Manag Care Spec Pharm. 2019;25(9):995–1000. doi: 10.18553/jmcp.2019.25.9.995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Alzahrani F, Sandaqji Y, Alharrah A, Alblowi R, Alrehaili S, Mohammed-Saeid W. Community pharmacies’ promotion of smoking cessation support services in Saudi Arabia: examining current practice and barriers. Healthcare. 2023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Vira P, Nazer L, Phung O, Jackevicius CA. A longitudinal evidence-based medicine curriculum and its impact on the attitudes and perceptions of student pharmacists. Am J Pharm Educ. 2019;83(1):6510. doi: 10.5688/ajpe6510 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Pringle J, Coley KC. Improving medication adherence: a framework for community pharmacy-based interventions. Integr Pharm Res Pract. 2015;4:175–83. doi: 10.2147/IPRP.S93036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Ramis M-A, Chang A, Nissen L. Strategies for teaching evidence-based practice to undergraduate health students: a systematic review protocol. JBI Database System Rev Implement Rep. 2015;13(2):12–25. doi: 10.11124/jbisrir-2015-1905 [DOI] [PubMed] [Google Scholar]
  • 45.Chandran V, Thunga G, Pai G, Khan S. Application and retention of evidence based practice skills: students and practitioner’s perspectives from an indian healthcare institution. Royal Society of Medicine. 2018. [Google Scholar]
  • 46.Poirier TI. A new vision for pharmacy education: it is time to shift the old paradigm and move forward. Am J Pharm Educ. 2007;71(5):103. doi: 10.5688/aj7105103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Hakam AM, Al-Ahmad MM. Evidence-based medicine as perceived by healthcare professionals: A cross-sectional study in the United Arab Emirates. Hosp Top. 2024;:1–11. doi: 10.1080/00185868.2024.2422118 [DOI] [PubMed] [Google Scholar]
  • 48.Wang C, Yao Y, Chen Y, Chen J. The impact of evidence-based medicine curricula on information literacy among clinical medical undergraduates and postgraduates in China. BMC Med Educ. 2025;25(1):520. doi: 10.1186/s12909-025-07125-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Alabdullah MN, Alabdullah H, Kamel S. Knowledge, attitude, and practice of evidence-based medicine among resident physicians in hospitals of Syria: a cross-sectional study. BMC Med Educ. 2022;22(1):785. doi: 10.1186/s12909-022-03840-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Liu K, Liu S, Ma Y, Jiang J, Liu Z, Wan Y. Comparison of blended learning and traditional lecture method on learning outcomes in the evidence-based medicine course: a comparative study. BMC Med Educ. 2024;24(1):680. doi: 10.1186/s12909-024-05659-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Shimizu T, Ueda M, Toyoyama M, Ohmori S, Takagaki N. Evaluation of an evidence-based medicine educational program for pharmacists and pharmacy students. Yakugaku Zasshi. 2018;138(5):655–66. doi: 10.1248/yakushi.17-00190-5 [DOI] [PubMed] [Google Scholar]
  • 52.Alotabi AJD, Alotaibi MBM, Khawaji GAA, Alhulayyil AA, Alanezi SA, Aldossary GI, et al. Integrating evidence-based practice into nursing school curricula: Review of educational strategies for enhancing competencies in evidence-based care delivery. JoE. 2024;3(8). doi: 10.62754/joe.v3i8.6132 [DOI] [Google Scholar]
  • 53.Malick S, Das K, Khan KS. Tips for teaching evidence-based medicine in a clinical setting: lessons from adult learning theory. Part two. J R Soc Med. 2008;101(11):536–43. doi: 10.1258/jrsm.2008.080713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ueda M, Takagaki N, Onda M, Arakawa Y, Shoji M, Ohmori S, et al. Introduction of team-based learning to evidence-based medicine educational course for pharmacy students. Yakugaku Zasshi. 2020;140(2):301–12. doi: 10.1248/yakushi.19-00152 [DOI] [PubMed] [Google Scholar]
  • 55.Cooper JB, Turner M, Patel M, Markle J, Amend C, Absher R, et al. Evaluation of an evidence-based medicine curriculum in a PGY1 pharmacy residency program using the Fresno Test. Am J Pharm Educ. 2018;82(5):6294. doi: 10.5688/ajpe6294 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Habtamu Setegn Ngusie

16 Jan 2025

PONE-D-24-39283Adoption of Evidence-Based Medicine: A Comparative Study of Hospital and Community Pharmacists in Saudi ArabiaPLOS ONE

Dear Dr. Alzahrani,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

As the editor, I would like to offer the following general comments:

Introduction: Please ensure that your introduction is scientifically sound. Begin with a general overview and then narrow down to specific details. Be sure to incorporate existing solutions to the problem, highlight the research gap, and reference previous studies.

Language Editing: I recommend enhancing the overall English language quality of your manuscript.

Abstract: Please revise your abstract to ensure it is more compelling and meets the journal's standards.

Thank you for your attention to these matters.

Please submit your revised manuscript by Mar 02 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Habtamu Setegn Ngusie

Academic Editor

PLOS ONE

Journal requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition ).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories .

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Actuality, Evidence Based Medicine has become an essential discipline for the decision-making process in the individual care of patients, with a judicious, and conscious use of the best scientific available evidence.

The relevance of this study takes root in the need to incorporate in an accurate way the basic knowledge of EBM into daily pharmacist’s practice. There are still few studies that evaluate the knowledge, attitudes and practices of pharmacists regarding the practice of EBM.

I consider that the document is written appropriately, presents a clear methodology, with adequate data analysis and presentation of results.

I don’t have any observation or consideration regarding the document.

Reviewer #2: The study employed convenience sampling and a combination of purposive and snowball sampling methods to select research subjects, which might lead to selection bias among respondents. Additionally, only 38.1% of the recruited samples were ultimately included in the analysis, thereby limiting the validity and representativeness of the results. Therefore, it is recommended to supplement the analysis with a comparative study of some of the unincluded samples to further clarify the authenticity and representativeness of the results.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 May 23;20(5):e0324620. doi: 10.1371/journal.pone.0324620.r003

Author response to Decision Letter 1


20 Jan 2025

Editor general comments:

i. Comment: Introduction: Please ensure that your introduction is scientifically sound. Begin with a general overview and then narrow down to specific details. Be sure to incorporate existing solutions to the problem, highlight the research gap, and reference previous studies.

Response: Thank you for your valuable feedback. We have thoroughly revised the introduction to make sure of scientific soundness and proper scholarly progression. Comment: Language Editing: I recommend enhancing the overall English language quality of your manuscript.

Response: Thank you for your valuable comment. We have carefully revised the manuscript to enhance its clarity, precision, and academic tone. Here are the specific improvements made.

ii. Comment: Abstract: Please revise your abstract to ensure it is more compelling and meets the journal’s standards.

Response: Thank you for your feedback. We have thoroughly revised the abstract to make it more compelling and aligned with journal standards.

Reviewer's Responses

Reviewer #1 Comments: Actuality, evidence-based medicine has become an essential discipline for the decision-making process in the individual care of patients, with judicious and conscious use of the best scientific evidence available.

The relevance of this study takes root in the need to incorporate in an accurate way the basic knowledge of EBM into daily pharmacist’s practice. There are still few studies that evaluate the knowledge, attitudes, and practices of pharmacists regarding the practice of EBM.

Responses: We appreciate your insights and have strengthened our manuscript to emphasize these important points better. First, we enhanced the introduction to establish the study's significance better. Second, we have strengthened the justification for the research gap.

Reviewer #2 comment: The study employed convenience sampling and a combination of purposive and snowball sampling methods to select research subjects, which might lead to selection bias among respondents. Additionally, only 38.1% of the recruited samples were ultimately included in the analysis, thereby limiting the validity and representativeness of the results. Therefore, it is recommended to supplement the analysis with a comparative study of some of the unincluded samples further to clarify the authenticity and representativeness of the results.

Response: We appreciate your concerns about the sampling methodology. This study used two sampling techniques: convenience and snowball sampling. We acknowledge that our initial manuscript incorrectly included purposive samplingand have removed this reference. The text in the manuscript has been updated.

Regarding selection bias although convenience sampling can introduce selection bias, our choice was informed by both practical considerations and methodological precedent in clinical and social settings.[1-3]. We have addressed this limitation by explicitly acknowledging it in our limitations section.

Concerning the suggestion to conduct a comparative analysis with unincluded samples, we must note that the majority of excluded responses were due to incomplete data, specifically where participants discontinued upon reaching questions about their educational qualifications.  

References

1. Stratton SJ. Population research: convenience sampling strategies. Prehospital and disaster Medicine. 2021;36(4):373-4.

2. Simkus J. Convenience sampling: Definition, method and examples. Retrieved Oktober. 2022;6:2022.

3. Etikan I, Musa SA, Alkassim RS. Comparison of convenience sampling and purposive sampling. American journal of theoretical and applied statistics. 2016;5(1):1-4.

Attachment

Submitted filename: Response to Reviwers.docx

pone.0324620.s002.docx (722.2KB, docx)

Decision Letter 1

Priti Chaudhary

26 Mar 2025

PONE-D-24-39283R1Adoption of Evidence-Based Medicine: A Comparative Study of Hospital and Community Pharmacists in Saudi ArabiaPLOS ONE

Dear Dr. Alzahrani,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Authors are required to reply all the queries, raised by the reviewers. Please submit your revised manuscript by May 10 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Priti Chaudhary, M.S.

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2:  1) The response rate after sampling in this study was only 38.15%, and the average age of the participants was relatively young (31 years old), so the representativeness of the research results is limited and there may be selective bias. It is suggested to supplement the overall number of research subjects that meet the inclusion and exclusion criteria, as well as compare the basic information of the sample obtained from this sampling with the overall population.

2) In addition, the research topic is a comparison between hospital and community pharmacists, and there is a lack of corresponding KAP comparison data in the results. Suggest adding baseline data comparison between hospitals and community pharmacists; Comparison of KAP survey results between hospital and community pharmacists.

Reviewer #3:  The manuscript titled "Adoption of Evidence-Based Medicine: A Comparative Study of Hospital and Community Pharmacists in Saudi Arabia" is well-structured and presents valuable insights into pharmacists' knowledge, attitudes, and practices regarding EBM. The study is methodologically sound, with clear objectives, a well-defined methodology, and a thorough statistical analysis. The discussion effectively interprets the results, comparing them with existing literature. However, some areas require improvement before recommending the manuscript for publication.

Major recommendations

Clarity and Consistency in Writing

• The manuscript is generally well-written, but some sections contain redundancy. For instance, in the introduction, the definition of EBM is repeated in multiple ways. Consider merging these statements for conciseness.

• Some sentences are overly long and complex, making them harder to follow. For example, in the introduction: "It combines the best available scientific evidence with the clinician's expertise and the patient's values to guide medical decisions effectively." This could be revised for better flow: "EBM integrates scientific evidence, clinical expertise, and patient values to improve medical decision-making."

Research Justification and Novelty

• The study’s importance is well-stated, but there is limited emphasis on the novelty of the research. Consider explicitly stating how this study fills a gap in previous research. For example:

o Does this study provide the first comparative analysis of hospital vs. community pharmacists in Saudi Arabia?

o How does it add to previous research findings on EBM adoption in pharmacy practice?

Strengthening this section will help establish the study's significance.

Methodology

• The response rate (38.15%) is relatively low. Was there any effort to mitigate potential non-response bias?

• The use of convenience and snowball sampling raises concerns about selection bias. While this is acknowledged, a stronger justification is needed to explain why this method was chosen over random sampling.

• The exclusion criteria are mentioned briefly. Were there any specific reasons for excluding pharmacists from the pharmaceutical industry or academia? Clarifying this will strengthen the study's rigor.

Statistical Analysis - Additional Clarifications

• The manuscript states that Bloom's threshold was used to categorize knowledge, attitude, and practice scores. While this is a reasonable approach, it would be beneficial to justify why this method was chosen over other classification methods.

• The use of net agreement and net frequency scores is well-documented, but some readers may not be familiar with these terms. Consider adding a brief explanation or reference in the Methods section.

• The effect size (Cohen’s d = 0.15 - 0.16) is interpreted as "small." This should be explicitly stated in the Results section, as some readers may not be familiar with effect size thresholds.

Interpretation of Findings

• The results indicate that pharmacists with less than one year of experience had higher EBM practice scores than more experienced pharmacists. This is an interesting finding but needs further exploration. Could it be that recent graduates receive better EBM training? If so, how can this be addressed in continuing education programs?

• Community pharmacists had lower EBM scores than hospital pharmacists. The manuscript attributes this to differences in professional settings, but other factors (e.g., lack of access to resources, workload differences) should be discussed in more depth.

• The misconception that EBM ignores clinical experience was reported by 41.7% of participants. This is a crucial barrier and should be highlighted in the discussion as a key area for intervention.

Practical Implications and Recommendations

• The manuscript does a good job of discussing barriers to EBM adoption, but the recommendations for overcoming these barriers are somewhat vague.

o What specific training strategies should be implemented?

o Would workshops, online courses, or mentorship programs be more effective?

o How can institutions support pharmacists in overcoming time constraints?

Adding specific recommendations will strengthen the manuscript's practical impact.

Minor Changes

Abstract:

o “EBM in Saudi Arabia’s pharmacies is an under-researched area despite its importance in pharmacy practice.”

o Consider rewording to: "Despite its importance in pharmacy practice, EBM adoption in Saudi Arabian pharmacies remains under-researched."

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 May 23;20(5):e0324620. doi: 10.1371/journal.pone.0324620.r005

Author response to Decision Letter 2


26 Apr 2025

Reviewer's Responses

Reviewer #2

1. Comments: The response rate after sampling in this study was only 38.15%, and the average age of the participants was relatively young (31 years old), so the representativeness of the research results is limited and there may be selective bias. It is suggested to supplement the overall number of research subjects that meet the inclusion and exclusion criteria, as well as compare the basic information of the sample obtained from this sampling with the overall population.

Responses: Thank you for this valuable comment. We acknowledge that the response rate of 38.15% and the relatively young average age of participants may limit the representativeness of our findings and introduce potential selection bias. We have addressed this limitation in the revised manuscript under the "Study Limitations" section.

Regarding the suggestion to supplement the number of research subjects and compare the basic characteristics of the sample with the overall population, we appreciate the recommendation. However, due to the design of our online survey using Google Forms' branching logic, we automatically excluded pharmacy technicians holding diploma degrees, a vital segment of the healthcare workforce in Saudi Arabia, along with individuals who declined participation or submitted incomplete surveys. The survey system immediately terminated responses for diploma holders after the education level question, and incomplete surveys were not stored in our database. Similarly, we have no demographic or comparative data for non-respondents. Therefore, while we recognize this as a significant limitation, we are unable to perform the suggested comparison between respondents and non-respondents or analyze potential differences between complete and incomplete survey responses. We have highlighted this limitation and recommended that future research use stratified sampling and larger, more inclusive datasets to enhance representativeness and allow for more detailed comparisons.

2. Comment: In addition, the research topic is a comparison between hospital and community pharmacists, and there is a lack of corresponding KAP comparison data in the results. Suggest adding baseline data comparison between hospitals and community pharmacists; Comparison of KAP survey results between hospital and community pharmacists.

Response: Thank you for your constructive feedback. We have addressed your concerns as follows:

1. Baseline Data Comparison:

We have expanded Table 1 to include detailed baseline demographic characteristics comparing hospital and community pharmacists.

2. KAP Survey Results Comparison:

We have enhanced our results section, which provides a detailed comparison of KAP scores between hospital and community pharmacists as follows:

a. Knowledge Domain:

Hospital pharmacists demonstrated significantly higher knowledge scores (M = 3.84, SD = 0.52) compared to community pharmacists (M = 3.70, SD = 0.57), with statistical significance (p = 0.03).

b. Attitude Domain:

No significant difference was observed in attitude scores between hospital pharmacists (M = 3.83, SD = 0.50) and community pharmacists (M = 3.76, SD = 0.53; p = 0.60).

c. Practice Domain:

Hospital pharmacists showed significantly higher practice scores (M = 3.89, SD = 0.51) compared to community pharmacists (M = 3.76, SD = 0.58; p = 0.02).

Reviewer #3

Clarity and Consistency in Writing

1. Comment: The manuscript is generally well-written, but some sections contain redundancy. For instance, in the introduction, the definition of EBM is repeated in multiple ways. Consider merging these statements for conciseness.

Response: Thank you for your comment. We have revised the introduction to be more concise by removing redundant definitions of EBM and streamlining the content.

2. Comment: Some sentences are overly long and complex, making them harder to follow. For example, in the introduction, "It combines the best available scientific evidence with the clinician's expertise and the patient's values to guide medical decisions effectively." This could be revised for better flow: "EBM integrates scientific evidence, clinical expertise, and patient values to improve medical decision-making."

Response: Thank you for your feedback. We have revised the sentence as suggested.

Research Justification and Novelty

3. Comment: The study’s importance is well-stated, but there is limited emphasis on the novelty of the research. Consider explicitly stating how this study fills a gap in previous research. For example:

a. Does this study provide the first comparative analysis of hospital vs. community pharmacists in Saudi Arabia?

b. How does it add to previous research findings on EBM adoption in pharmacy practice?

Strengthening this section will help establish the study's significance.

Response: We appreciate your feedback. Thank you for your input. We have revised our manuscript to emphasize the significance of our study, particularly highlighting its status as the first comparative analysis of EBM adoption between hospitals and community pharmacists in Saudi Arabia, in both the concluding paragraph of the introduction and the opening section of the discussion. In addition, we have revised the discussion section to illustrate what our study adds to previous research.

Methodology

4. Comment: The response rate (38.15%) is relatively low. Was there any effort to mitigate potential non-response bias?

Response: Thank you for your valuable comment. While our response rate of 38.15% is lower than ideal, it aligns with similar pharmacy practice surveys conducted in Saudi Arabia. For instance, Al-Jazairi and Alharbi reported a 20% response rate among hospital pharmacists when assessing evidence-based practice [1]. Another cross-sectional study targeting hospital pharmacists yielded a response rate of 14.8% [2]. Additionally, the “National Survey of Drug Information Centers Practice in Saudi Arabia” reported a 40% response rate, involving pharmacists in drug information centers, which may include community pharmacists [3]. This limitation has been explicitly addressed in the revised manuscript, highlighting its potential implications for the generalizability and interpretation of the study findings.

5. Comment: The use of convenience and snowball sampling raises concerns about selection bias. While this is acknowledged, a stronger justification is needed to explain why this method was chosen over random sampling.

Response: While random sampling would be ideal, convenience and snowball sampling were employed due to several context-specific challenges. First, there was no comprehensive, accessible sampling frame of pharmacists in Saudi Arabia. For instance, Fathelrahman conducted a nationwide cross-sectional study assessing medical device-related counseling practices among community pharmacists in Saudi Arabia [4]. They employed convenience sampling due to the lack of a national registry or contact database for pharmacists, which prevented the use of probability sampling methods and stratification by geographical region. This limitation underscores the challenges in obtaining a representative sample of pharmacists in specific regions like the Madinah region of Saudi Arabia. Consequently, our study utilized convenience and snowball sampling techniques to reach pharmacists across diverse practice settings, particularly community pharmacists who are typically harder to access through institutional channels. While this approach may introduce selection bias, it aligns with established practices in pharmacy research where complete listings of the target population are unavailable. The Study Sampling and Response Rate section has been updated to reflect this rationale.

6. Comment: The exclusion criteria are mentioned briefly. Were there any specific reasons for excluding pharmacists from the pharmaceutical industry or academia? Clarifying this will strengthen the study's rigor.

Response: Thank you for your observation. Our study specifically focused on hospital and community pharmacists, as they are the primary healthcare professionals actively involved in patient care and clinical decision-making informed by evidence-based medicine (EBM). This choice is supported by prior research indicating that these pharmacists are key users of EBM in daily practice, particularly in medication therapy management, clinical interventions, and patient-centered care [5, 6]. Pharmacists working in industry and academia were excluded, as they typically do not hold active patient care licenses and are not routinely engaged in clinical decision-making that necessitates EBM application. This exclusion aligns with the methodology of similar studies investigating EBM use among frontline healthcare providers, which have similarly omitted participants from non-clinical sectors [7-9]. By targeting licensed pharmacists involved in direct patient care, our study offers a more accurate reflection of EBM implementation in routine pharmacy practice. We have clarified this rationale in the revised Study Population subsection of the Methods section to enhance transparency and methodological rigor.

Statistical Analysis - Additional Clarifications

7. Comment: The manuscript states that Bloom's threshold was used to categorize knowledge, attitude, and practice scores. While this is a reasonable approach, it would be beneficial to justify why this method was chosen over other classification methods.

Response: Thank you for this thoughtful comment. The use of Bloom's threshold in categorizing knowledge, attitude, and practice (KAP) scores is a common methodological approach in cross-sectional studies, as demonstrated by multiple sources, particularly in the absence of standardized benchmarks [10-13]. While none of the provided studies explicitly justify why Bloom’s cut-off was selected over other classification methods, their consistent application of this method supports its validity as a standardized tool in KAP research. We have added a brief justification in the Methods section to clarify the rationale for this choice.

Comment: The use of net agreement and net frequency scores is well-documented, but some readers may not be familiar with these terms. Consider adding a brief explanation or reference in the Methods section.

Response: Thank you for your helpful comment. We have added a short explanation and supporting reference in the Methods section to define these measures and their relevance in KAP studies.

8. Comment: The effect size (Cohen’s d = 0.15 - 0.16) is interpreted as "small." This should be explicitly stated in the Results section, as some readers may not be familiar with effect size thresholds.

Response: Thank you for the comment. Cohen’s d is a commonly used measure of effect size that indicates the standardized difference between two means. According to Cohen’s (1988) guidelines, an effect size of 0.2 is considered small, 0.5 is medium, and 0.8 or above is large. A small effect (d ≈ 0.2) suggests a modest difference between groups that, while statistically significant, may have limited practical significance [14]. We have revised the Methods and Results sections to clearly state that the observed effect sizes fall within the small range.

Interpretation of Findings

9. Comment: The results indicate that pharmacists with less than one year of experience had higher EBM practice scores than more experienced pharmacists. This is an interesting finding but needs further exploration. Could it be that recent graduates receive better EBM training? If so, how can this be addressed in continuing education programs?

Response: Thank you for this thoughtful and insightful comment. We agree that the finding warrants further exploration. One possible explanation is that recent graduates may have received more formal and updated training in evidence-based medicine (EBM) as part of evolving pharmacy curricula [14-16]. In contrast, pharmacists with more years of experience may not have had the same level of EBM emphasis during their initial training, which may explain the lower practice scores among this group. This trend is consistent with findings in other health professions, where integrated EBM curricula have been shown to significantly improve information literacy and evidence application skills among students and recent graduates [17]. This highlights a potential gap in ongoing professional development and underscores the importance of integrating targeted EBM content into continuing education and professional development programs. We have expanded the Discussion section to include this interpretation and its implications.

10. Comment: Community pharmacists had lower EBM scores than hospital pharmacists. The manuscript attributes this to differences in professional settings, but other factors (e.g., lack of access to resources, workload differences) should be discussed in more depth.

Response: Thank you for your comment. We do agree that the observed differences in EBM scores between community and hospital pharmacists may be influenced by a broader range of factors beyond the practice setting alone. Community pharmacists often face barriers such as limited access to clinical resources, lack of institutional support, and higher workload and time constraints, which may hinder their ability to engage with EBM regularly. In contrast, hospital pharmacists may have better access to multidisciplinary teams, structured protocols, and clinical decision-support tools. We have expanded the Discussion section to reflect these considerations and provide a more comprehensive interpretation of the findings.

11. Comment: The misconception that EBM ignores clinical experience was reported by 41.7% of participants. This is a crucial barrier and should be highlighted in the discussion as a key area for intervention.

Response: Thank you for your observation. We have emphasized this point in the revised Discussion section and identified it as a key area for educational and institutional intervention.

Practical Implications and Recommendations

12. Comment: The manuscript does a good job of discussing barriers to EBM adoption, but the recommendations for overcoming these barriers are somewhat vague.

a. What specific training strategies should be implemented?

b. Would workshops, online courses, or mentorship programs be more effective?

c. How can institutions support pharmacists in overcoming time constraints?

Response: We appreciate your comment. We have expanded the Discussion section to include evidence-based strategies for overcoming key barriers to EBM adoption. For training, structured continuing education programs that combine interactive workshops, case-based learning, and evidence retrieval exercises are recommended. Online courses and webinars offer flexibility and broad accessibility, especially for community pharmacists. Mentorship programs led by experienced clinical pharmacists can also provide personalized guidance and reinforce practical application. To address time constraints, institutions can support EBM practice by integrating clinical decision support tools into pharmacy workflows, allocating protected time for professional development, and fostering a culture that values evidence-based care. These enhancements have been added to the revised manuscript to provide a more comprehensive roadmap for improving EBM uptake.

Minor Changes

Abstract:

13. Comment: EBM in Saudi Arabia’s pharmacies is an under-researched area despite its importance in pharmacy practice.” Consider rewording to: "Despite its importance in pharmacy practice, EBM adoption in Saudi Arabian pharmacies remains under-researched."

Response: Thank you for the suggestion. The sentence has been updated to: “Despite its importance in pharmacy practice, EBM adoption in Saudi Arabian pharmacies remains under-researched.”

References

1. Al-Jazairi AS, Alharbi R. Assessment of evidence-based practice among hospital pharmacists in Saudi Arabia: attitude, awareness, and practice. International Journal of Clinical Pharmacy. 2017;39:712-21.

2. Ajabnoor AM, Cooper RJ. Pharmacists’ prescribing in Saudi Arabia: cross-sectional study describing current practices and future perspectives. Pharmacy. 2020;8(3):160.

3. Alomi Y, Alghamdi S, Alattyh R. National Survey of Drug

Attachment

Submitted filename: Response to Reviwers (2).docx

pone.0324620.s003.docx (738.2KB, docx)

Decision Letter 2

Priti Chaudhary

29 Apr 2025

Adoption of Evidence-Based Medicine: A Comparative Study of Hospital and Community Pharmacists in Saudi Arabia

PONE-D-24-39283R2

Dear Dr. Fahad Alzahrani,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Priti Chaudhary, M.S.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Priti Chaudhary

PONE-D-24-39283R2

PLOS ONE

Dear Dr. Alzahrani,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Priti Chaudhary

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviwers.docx

    pone.0324620.s002.docx (722.2KB, docx)
    Attachment

    Submitted filename: Response to Reviwers (2).docx

    pone.0324620.s003.docx (738.2KB, docx)

    Data Availability Statement

    All relevant data are within the article and its Supporting Information files. The datasets necessary to replicate the study findings and the supporting files have also been deposited in the Zenodo public data repository. The data can be accessed at the following DOI: 10.5281/zenodo.15332654.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES